The present invention relates to the field of cancer therapy. Specifically,provided are methods of treating cancer in asubject having clinical signs of bone marrow homing of myeloid cells,including neutropenia, isolated neutropenia, a low percentage ofperipheral blood blasts with or without a high percentage of bone marrowblasts, and/or a low ratio of peripheral blood blasts to bonemarrow blasts, with a farnesyltransferase inhibitor (FTI) that includedetermining whether the subject is likely to be responsive to theFTI treatment based on hematological characteristics indicating bone marrowhoming of myeloid cells.
